SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Caveat Emptor who wrote (288)7/16/1998 11:11:00 AM
From: Harold Engstrom  Read Replies (2) | Respond to of 410
 
Caveat Emptor, why the one man crusade about Genzyme insider trading? If you have something to say, then say it.



To: Caveat Emptor who wrote (288)7/16/1998 11:12:00 AM
From: Dave Chanoux  Respond to of 410
 
Regarding who are these people:

From the 1995 Genzyme Annual Report and Form 10-K:

Geoffrey F. Cox, Ph.D - Senior Vice President, Operations and Genzyme Pharmaceuticals

Gregory D. Phelps - Senior Vice President; President, Genzyme Tissue Repair.

Neither is listed in the 1997 annual report.

Regards,

Dave Chanoux



To: Caveat Emptor who wrote (288)7/16/1998 12:07:00 PM
From: H. Bradley Toland, Jr.  Respond to of 410
 
C Emptor

G. Cox took a CEO job in Texas, with Aronex I think. Don't know where Phelps went.

They may have done quite nicely, depending on price they paid for stock.

Again, I'll tell you that you can have all your questions answered by simply calling Steve Push at Genzyme, he'll be happy to talk with you.

By the way, what do you think of the recent Pharming announcement? It should make short sellers pause!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News